These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 26806798)

  • 21. Generalized Safety and Efficacy of Simplified Intravenous Thrombolysis Treatment (SMART) Criteria in Acute Ischemic Stroke: The MULTI SMART Study.
    Sørensen SB; Barazangi N; Chen C; Wong C; Grosvenor D; Rose J; Bedenk A; Morrow M; McDermott D; Hove JD; Tong DC
    J Stroke Cerebrovasc Dis; 2016 May; 25(5):1110-1118. PubMed ID: 26897101
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Validation of FLAIR hyperintense lesions as imaging biomarkers to predict the outcome of acute stroke after intra-arterial thrombolysis following intravenous tissue plasminogen activator.
    Chung JW; Kim KJ; Noh WY; Jang MS; Yang MH; Han MK; Kwon OK; Jung C; Kim JH; Oh CW; Lee JS; Lee J; Bae HJ
    Cerebrovasc Dis; 2013; 35(5):461-8. PubMed ID: 23735898
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Door-to-needle times for tissue plasminogen activator administration and clinical outcomes in acute ischemic stroke before and after a quality improvement initiative.
    Fonarow GC; Zhao X; Smith EE; Saver JL; Reeves MJ; Bhatt DL; Xian Y; Hernandez AF; Peterson ED; Schwamm LH
    JAMA; 2014 Apr 23-30; 311(16):1632-40. PubMed ID: 24756513
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Characteristics of the Drip-and-Ship Paradigm for Patients with Acute Ischemic Stroke in South Korea.
    Park MS; Lee JS; Park TH; Cho YJ; Hong KS; Park JM; Kang K; Lee KB; Kim JG; Lee SJ; Lee J; Choi KH; Kim JT; Cho KH; Oh MS; Yu KH; Lee BC; Cha JK; Kim DH; Nah HW; Lee J; Kim DE; Ryu WS; Kim BJ; Han MK; Bae HJ; Song SK; Choi JC
    J Stroke Cerebrovasc Dis; 2016 Nov; 25(11):2678-2687. PubMed ID: 27480820
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Thrombolysis for Ischemic Stroke during Pregnancy: A Case Report and Review of the Literature.
    Tversky S; Libman RB; Reppucci ML; Tufano AM; Katz JM
    J Stroke Cerebrovasc Dis; 2016 Oct; 25(10):e167-70. PubMed ID: 27523596
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparison of combined venous and arterial thrombolysis with primary arterial therapy using recombinant tissue plasminogen activator in acute ischemic stroke.
    Wolfe T; Suarez JI; Tarr RW; Welter E; Landis D; Sunshine JL; Zaidat OO
    J Stroke Cerebrovasc Dis; 2008; 17(3):121-8. PubMed ID: 18436152
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinical Deterioration and Early Imaging Changes after Intravenous Tissue Plasminogen Activator Administration in Acute Ischemic Stroke Patients.
    Chou C; Bourekas EC; Slivka A
    J Stroke Cerebrovasc Dis; 2016 Jul; 25(7):1823-1827. PubMed ID: 27133771
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Local intra-arterial thrombolysis with urokinase for acute ischemic stroke before and after the approval of intravenous tissue plasminogen activator treatment in Taiwan.
    Yang FC; Lin CC; Hsueh CJ; Lee JT; Hsu CH; Lee KW; Peng GS
    Ann Vasc Surg; 2010 Nov; 24(8):1117-24. PubMed ID: 21035704
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Computed Tomography--Verified Leukoaraiosis Is a Risk Factor for Post-thrombolytic Hemorrhage.
    Willer L; Havsteen I; Ovesen C; Christensen AF; Christensen H
    J Stroke Cerebrovasc Dis; 2015 Jun; 24(6):1126-30. PubMed ID: 25920756
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Angiographic analysis of intravascular thrombus volume in patients with acute ischemic stroke.
    Qureshi AI; Alkawi A; Hussein HM; Divani AA
    J Endovasc Ther; 2007 Aug; 14(4):475-82. PubMed ID: 17696621
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Current status of intravenous thrombolysis for acute ischemic stroke in Asia.
    Sharma VK; Ng KW; Venketasubramanian N; Saqqur M; Teoh HL; Kaul S; Srivastava PM; Sergentanis T; Suwanwela N; Nguyen TH; Lawrence Wong KS; Chan BP
    Int J Stroke; 2011 Dec; 6(6):523-30. PubMed ID: 22111797
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Acute stroke imaging for thrombolytic therapy--an update.
    Köhrmann M; Jüttler E; Huttner HB; Nowe T; Schellinger PD
    Cerebrovasc Dis; 2007; 24(2-3):161-9. PubMed ID: 17596684
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Race/Ethnic differences in the risk of hemorrhagic complications among patients with ischemic stroke receiving thrombolytic therapy.
    Mehta RH; Cox M; Smith EE; Xian Y; Bhatt DL; Fonarow GC; Peterson ED;
    Stroke; 2014 Aug; 45(8):2263-9. PubMed ID: 25070958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of off-label stroke treatment with tissue plasminogen activator.
    Kvistad CE; Logallo N; Thomassen L; Waje-Andreassen U; Brøgger J; Naess H
    Acta Neurol Scand; 2013 Jul; 128(1):48-53. PubMed ID: 23311439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Tissue plasminogen activator overdose in acute ischemic stroke patients linked to poorer functional outcomes.
    Sahlas DJ; Gould L; Swartz RH; Mohammed N; McNicoll-Whiteman R; Naufal F; Oczkowski W
    J Stroke Cerebrovasc Dis; 2014 Jan; 23(1):155-9. PubMed ID: 23375748
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Utility of early post-treatment single-photon emission computed tomography imaging to predict outcome in stroke patients treated with intravenous tissue plasminogen activator.
    Abumiya T; Katoh M; Moriwaki T; Yoshino M; Aoki T; Imamura H; Aida T; Scichinohe H; Nakayama N; Kazumata K; Houkin K
    J Stroke Cerebrovasc Dis; 2014; 23(5):896-901. PubMed ID: 24045082
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Safety of tPA in stroke mimics and neuroimaging-negative cerebral ischemia: swift or sure? The acceptable rate of neurovascular mimics among IV tPA-treated patients.
    Martinez-Ramirez S; Delgado-Mederos R; Martí-Vilalta JL; Martí-Fàbregas J
    Neurology; 2010 Nov; 75(20):1853; author reply 1854. PubMed ID: 21079190
    [No Abstract]   [Full Text] [Related]  

  • 38. Preclusion of ischemic stroke patients from intravenous tissue plasminogen activator treatment for mild symptoms should not be based on low National Institutes of Health Stroke Scale Scores.
    Wendt M; Tütüncü S; Fiebach JB; Scheitz JF; Audebert HJ; Nolte CH
    J Stroke Cerebrovasc Dis; 2013 May; 22(4):550-3. PubMed ID: 23433783
    [TBL] [Abstract][Full Text] [Related]  

  • 39. tPA Mobilizes Immune Cells That Exacerbate Hemorrhagic Transformation in Stroke.
    Shi K; Zou M; Jia DM; Shi S; Yang X; Liu Q; Dong JF; Sheth KN; Wang X; Shi FD
    Circ Res; 2021 Jan; 128(1):62-75. PubMed ID: 33070717
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Standard-dose intravenous tissue-type plasminogen activator for stroke is better than low doses.
    Liao X; Wang Y; Pan Y; Wang C; Zhao X; Wang DZ; Wang C; Liu L; Wang Y;
    Stroke; 2014 Aug; 45(8):2354-8. PubMed ID: 25013020
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.